Personalized Genetic Testing in Miami provides the invaluable service of personalized genetic medicine testing to physicians and patients throughout the U.S.
Thousands of Tests Performed
Providing doctors with the information needed to determine the best medicines and treatments for each of their patients.
20+ Years Experience
Experience in biotechnology, pharmaceutical, hematology, flow cytometry, clinical molecular biology, immunology, and chemistry industries.
Fast 5-Day Turnaround
Using the latest technologies from the leaders in the industry, our process is 3 times faster than competitor’s analysis methods.
Accurate Reporting
Through Coriell Institute, backed by over 60 years of research experience providing the quality control required for validation in pharmacogenetics testing.
Personalized Genetic Testing provides a wide range of personalized medicine genetic testing and pharmacogenomics testing. Examples of what patients can be tested for include:
CARDIOVASCULAR DRUGS
SOMATIC MUTATIONS
ONCOLOGY MEDICATIONS
PSYCHOTROPIC MEDICATIONS
PAIN MANAGEMENT DRUGS
DIABETES MEDICATIONS
APOE GENE
Determine Risk of Vascular Disease
FACTOR V LEIDEN
Determine Risk of Thrombosis
MTHFR
Determine risk factor for cardiovascular disease
COMT
Enzyme that degrades dopamine and norepinephrine
PGT’s genetic medication testing supports doctors in determining the appropriate medications and doses that are best suited for a patient’s genetic profile.
PGT Comprehensive Panel provides genetic results for:
| CYP2D6 | CYP2D6 testing has been revealed to have an important outcome on the body’s ability to metabolize opioids such as Oxycodone, Codeine, and Tramadol. |
| CYP2C19 | Has been connected to the metabolism of Carisoprodol, a skeletal muscle relaxant. Genetic testing medication assists in determining the appropriate personalised medicine therapies. |
| CYP2C9 | CYP2C9 customized medicine testing is done for those taking the most common pain medications as it is responsible for the metabolism of most NSAID pain medications. |
| CYP3A4/A5 | Medication genetic testing is done for those taking narcotics for severe pain as it affects the body’s ability to metabolize Fentanyl. Genetic testing medication metabolism can assist in prescribing the right dose of these type of medications. |
| CYP1A2 | Is primarily responsible for clozapine metabolism. The genetic studies of clozapine drug response are supported by the identification of multiple functional variants in CYP1A2, with well-defined effects on clozapine metabolism. |
|
SLCO1B1 |
An influx transporter that moves drugs into cells. Variations may affect the blood levels of drugs that are substrates for this transporter. Testing can be done for those that take common classes of medications such as Statins as these are mostly affected. Genetic lab testing can help to determine interactions and individual medicine treatment. |
|
VKORC1 |
Made primarily in the liver, the gene provides instructions for making a vitamin K epoxide reductase enzyme. |
|
CYP2B6 |
Responsible for the metabolism of the most active metabolite of bupropion. Personal medicine gene testing can help determine appropriate doses of these types of medication. |
|
COMT |
An enzyme that degrades dopamine and norepinephrine, primarily in the prefrontal cortex of the brain a pharmacodynamic gen which has been implicated in the therapeutic response of patients taking stimulant medications (amphetamines) and some antipsychotics. |
|
F2/Factor II |
Prothrombin deficiency, thus creating the potential of a hypercoagulable state. |
|
F5/Factor V Leiden |
Inherited Thrombophilia. Factor V Leiden mutation is the greatest common inherited predisposition for hypercoagulability. People with Factor V Leiden mutation with thrombophilia have higher than average risk of developing a blood clot called a deep venosus thrombosis (DVT). |
|
MTHFR |
A decrease in the function or amount of MTHFR causes increased blood levels of homocysteine. Increased homocysteine blood concentrations are associated with an increased risk for cardiovascular disease including venous thrombosis, atherosclerosis, stroke, and peripheral artery disease. |
|
OPRM1 |
Has been associated with the therapeutic response of patients taking opioid medications. Customized medical testing for medication effectiveness can help determine proper dosing. |
|
ANKK1 |
ANKK1 testing is used to determine risk factors for addictive disorders, with obesity and with the performance of executive functions. Gene testing can help to determine customized medical treatment. |
|
APOE |
People who carry APOE have an increased chance of developing atherosclerosis, and to greatly increase the risk of a rare condition called hyperlipoproteinemia type III. Hyperlipoproteinemia type III is characterized by increased blood levels of cholesterol, certain fats called triglycerides, and molecules called beta-very low-density lipoproteins (beta-VLDLs), which carry cholesterol and lipoproteins in the bloodstream. |
